# Cencora: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Cencora, Inc. · NYSE: COR · Sector: Health Care

Updated for Q4 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/cencora. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Cencora: how the business works", with the page URL.

## The 30-second summary

Cencora, formerly AmerisourceBergen, buys medicines from drug makers and delivers them to pharmacies, hospitals and doctors, mostly in the US. FY2026 revenue was $337.4 billion. It kept $4.11 of gross profit per $100 of FY2026 revenue. Specialty drugs kept $11.76 per $100, against $2.41 in drug wholesale. Walgreens and Boots were about 25% of FY2025 revenue.

## 5 points

- **What it sells:** Cencora buys medicines in bulk from drug makers and delivers them to pharmacies, hospitals, clinics and doctors, mostly in the US; FY2026 revenue was $337.4 billion. [S4, S15]
- **Who pays it:** In FY2026, drug wholesale customers paid 84.3% of Cencora's revenue, specialty-drug and doctor-practice customers 13.5%, and the animal-health and other businesses 2.6%. [S22]
- **What it keeps from $100:** Of every $100 that came in during FY2026, Cencora kept $1.03 as net income, including a $1.1 billion one-time gain on OneOncology; operating income was $3.9 billion. [S15]
- **Where the operating profit comes from:** Pharmaceutical Distribution and Services brought 84.3% of FY2026 revenue but kept 0.96% of it as operating income, while Specialty Pharmaceutical and Provider Services kept 3.73% on 13.5% of revenue. [S22]
- **The one thing to watch:** Borrowings reached $11.3 billion at Sep 30, 2026 after the OneOncology deal, and on Oct 21, 2026 Cencora, which holds about 4% of American Oncology Network, agreed to buy the rest at an enterprise value of $2.4 billion. [S15, S23]

## What does Cencora sell?

Cencora buys medicines in bulk from drug makers and delivers them to pharmacies, hospitals, clinics and doctors, mostly in the US. It also runs specialty-drug services for cancer and eye doctors, a European wholesaler and a courier for medicines.

- **US drug wholesale:** Brand-name and generic medicines delivered to pharmacies and health systems. Good Neighbor Pharmacy is its franchise program for independent pharmacies. [S4]
- **Specialty drugs and doctor services:** Cancer, eye, plasma and vaccine products for clinics and specialists. It also owns RCA and OneOncology, which run the business side of eye and cancer practices. [S4, S1]
- **International:** Alliance Healthcare, a drug wholesaler in Europe, plus World Courier, which provides specialty transport and logistics for drug makers worldwide. [S4]
- **Other businesses:** MWI Animal Health supplies vets and farms; a stake in Profarma, a Brazilian distributor, is being sold. [S4, S15]

## Who pays Cencora?

- **Walgreens and Boots (25.0% of revenue):** The pharmacy chains of Walgreens Boots Alliance buy brand-name and generic medicines under a distribution agreement that runs to 2029. [S4, S25]
- **Evernorth Health Services (13.0% of revenue):** The company's second-largest customer in FY2025, the 10-K says. [S4]
- **Other pharmacies, hospitals, clinics, doctors and vets:** Independent and chain pharmacies, health systems, cancer and eye practices, and animal-health customers make up the rest. [S4]
- **Customer concentration:** largest customer 25.0%, top 10 66.0% of revenue. Walgreens and Boots were about 25% of FY2025 revenue and 38% of money owed to Cencora at Sep 30, 2025. The top 10 customers, including government agencies and buying groups, were about 66%. [S4, S25]

## Where the money went (FY2026)

1. Pharmacies, hospitals and doctors paid Cencora $337.4 billion in FY2026.
2. About $323.5 billion went back to drug makers for the medicines it resold.
3. Warehouses, delivery, staff and offices took $9.1 billion, including wear-and-tear of assets.
4. Deal costs, restructuring, a write-down, interest and tax took another $2.4 billion.
5. A $1.1 billion one-time gain on OneOncology helped leave $3.5 billion of net income.

Sources: S15.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Sep 30 (it runs October to September). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 | 213,988.8 | 2,859.4 | 1.3% | 1,539.9 | 0.7% | 7.39 | 2,666.6 | 438.2 | 2,228.4 | S14 |
| FY2022 | 238,587 | 3,060.3 | 1.3% | 1,698.8 | 0.7% | 8.04 | 2,703.1 | 496.3 | 2,206.8 | S13 |
| FY2023 | 262,173.4 | 3,304.6 | 1.3% | 1,745.3 | 0.7% | 8.53 | 3,911.3 | 458.4 | 3,453 | S12 |
| FY2024 | 293,958.6 | 3,267.2 | 1.1% | 1,509.1 | 0.5% | 7.53 | 3,484.7 | 487.2 | 2,997.5 | S8 |
| FY2025 | 321,332.8 | 3,679.7 | 1.1% | 1,554.2 | 0.5% | 7.96 | 3,875.1 | 668 | 3,207.1 | S4 |
| FY2026 | 337,397.3 | 4,975.5 | 1.5% | 3,483.9 | 1.0% | 17.95 | 4,790.2 | 909.5 | 3,880.7 | S15 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

At Sep 30, 2026, Cencora's borrowings of $11.3 billion exceeded its cash by $6.4 billion, about 1.3 years of FY2026 operating cash flow (Cityfort calculation from Q4 FY2026 earnings release). [S15]

| Item | Value |
| --- | --- |
| Total debt | 11,266.1 |
| Cash and investments | 4,880.3 |
| Net debt (debt minus cash) | 6,385.8 |
| Net worth (shareholders' money) | 3,681.2 |
| Debt to equity (times) | 3.06 |
| Interest cover (times) | 8 |

- Net debt rose from $3.3 billion a year earlier (Cityfort calculation from Q4 FY2026 earnings release); $3.0 billion of senior notes and $1.5 billion of term loans paid for OneOncology.
- Unpaid bills to suppliers, $58.0 billion, are its largest liability and are not counted as debt.
- A further $3.7 billion was booked as long-term accrued litigation liability, also outside debt.
- Goodwill and other intangibles (the price paid for acquisitions above their asset value) reached $22.5 billion, about six times equity (Cityfort calculation from Q4 FY2026 earnings release).
- Interest coverage is FY2026 operating income of $3.9 billion divided by $490 million of net interest expense (Cityfort calculation from Q4 FY2026 earnings release).
- Equity of $3.7 billion includes minority partners; $3.9 billion of assets held for sale (businesses being sold) are not counted as cash.

## Who owns Cencora? (as of Nov 30, 2025)

Cencora has one class of common stock with one vote per share. The 15 directors and executive officers held 743,823 shares at Nov 30, 2025, under 1% of the 194,526,076 shares at Jan 12, 2026 (0.38%: Cityfort calculation from 2026 proxy statement). Walgreens Boots Alliance stopped holding over 5% in June 2025. [S25, S1, S4]

- Officers and directors (as a group), shares: 0.38%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (190,827,165 shares at Jul 31, 2026 (Q3 FY2026 10-Q cover), down from 193,937,673 at Sep 30, 2025.) | 190.83 | 1 | — | — | Yes | S1, S4 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The Vanguard Group | 11.6% | — | Jul 29, 2025 | 22,478,981 shares, from a Schedule 13G/A filed Jul 29, 2025, as listed in the 2026 proxy. | S25 |
| BlackRock, Inc. | 8.4% | — | Jan 31, 2025 | 16,405,771 shares, from a Schedule 13G/A filed Jan 31, 2025, as listed in the 2026 proxy. | S25 |

## What could go wrong

### One customer is a quarter of sales

Walgreens and Boots were about 25% of FY2025 revenue and 38% of money owed to Cencora. Sycamore Partners bought Walgreens Boots Alliance on Aug 28, 2025. [S4, S25]

What to watch: Walgreens' share of revenue in the FY2026 10-K, and any change to the contracts that run to 2029.

### Very thin margins

Gross profit was $4.11 per $100 of FY2026 revenue, and net income about $1. Small changes in drug prices or supplier terms move profit a lot. [S15]

What to watch: Gross profit per $100 in the next quarterly results.

### Opioid and other litigation

Long-term accrued litigation liability, mostly for opioid matters, was $3.7 billion at Sep 30, 2026. [S15]

What to watch: Accrued litigation liability and new verdicts in the 10-K.

### More debt and acquisition risk

Net debt rose to $6.4 billion after OneOncology (Cityfort calculation from Q4 FY2026 earnings release). It booked write-downs on PharmaLex of $418 million (FY2024) and $724 million (FY2025), and $249 million in FY2026 on its U.S. Consulting Services business, sold in April 2026. [S15, S4]

What to watch: Further write-downs, and the cost of the pending American Oncology Network deal.

### Many moving parts at once

The MWI–Covetrus merger is under FTC review, Profarma is being sold, and new segments apply from Oct 1, 2026. Older segment figures do not compare directly. [S1, S15, S22]

What to watch: Closing dates for the MWI–Covetrus merger and the Profarma sale.

### Foreign currency

About 9% of FY2025 revenue came from outside the US, in currencies including the pound, euro and Turkish lira. Cencora recorded a Türkiye currency remeasurement expense of $53.9 million in FY2026. [S4, S15]

What to watch: Currency effects in International results.

## What to watch

Next: Q1 FY2027 results, Date not announced yet.

- **Walgreens' share of revenue:** Walgreens and Boots were about 25% of FY2025 revenue. The FY2026 10-K, not yet filed on Nov 20, 2026, will give the FY2026 share.
- **Deals closing:** In its Nov 4, 2026 guidance Cencora assumed the Profarma sale closes in Q1 FY2027 and the MWI–Covetrus merger on Mar 31, 2027. On Oct 21, 2026 it agreed to buy the American Oncology Network shares it does not already own.
- **Borrowings:** Borrowings were $11.3 billion at Sep 30, 2026, and net debt $6.4 billion (Cityfort calculation from Q4 FY2026 earnings release). Cencora said in its Oct 21, 2026 deal announcement that it expects to pay about $1.7 billion to raise its American Oncology Network stake to 75%, if other holders keep 25%.
- **Results against the company's range:** Management said in the Nov 4, 2026 earnings release that it expects FY2027 revenue growth of 3% to 5% and adjusted EPS of $19.40 to $19.75.

## Sources

- S1: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085926000034/0001140859-26-000034-index.htm (published Aug 5, 2026)
- S2: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085926000020/0001140859-26-000020-index.htm (published May 6, 2026)
- S3: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085926000006/0001140859-26-000006-index.htm (published Feb 4, 2026)
- S4: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085925000131/0001140859-25-000131-index.htm (published Nov 25, 2025)
- S5: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085925000122/0001140859-25-000122-index.htm (published Aug 6, 2025)
- S6: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085925000083/0001140859-25-000083-index.htm (published May 7, 2025)
- S7: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085925000034/0001140859-25-000034-index.htm (published Feb 5, 2025)
- S8: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085924000177/0001140859-24-000177-index.htm (published Nov 26, 2024)
- S9: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085924000119/0001140859-24-000119-index.htm (published Jul 31, 2024)
- S10: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085924000072/0001140859-24-000072-index.htm (published May 1, 2024)
- S11: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085924000019/0001140859-24-000019-index.htm (published Jan 31, 2024)
- S12: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085923000197/0001140859-23-000197-index.htm (published Nov 21, 2023)
- S13: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085922000098/0001140859-22-000098-index.htm (published Nov 22, 2022)
- S14: Form 10-K for FY2021. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085921000058/0001140859-21-000058-index.htm (published Nov 23, 2021)
- S15: Q4 FY2026 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085926000038/exhibit991-q42026.htm (published Nov 4, 2026)
- S16: Q3 FY2026 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085926000032/exhibit991-q32026.htm (published Aug 5, 2026)
- S17: Q2 FY2026 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085926000018/exhibit991-q22026.htm (published May 6, 2026)
- S18: Q1 FY2026 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085926000004/exhibit991-q12026.htm (published Feb 4, 2026)
- S19: Q4 FY2025 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085925000128/exhibit991-q42025.htm (published Nov 5, 2025)
- S20: Q3 FY2025 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085925000119/exhibit991-q32025.htm (published Aug 6, 2025)
- S21: Q2 FY2025 earnings release (8-K Exhibit 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085925000081/exhibit991-q22025.htm (published May 7, 2025)
- S22: Revised reportable segments, FY2025 and FY2026 recast (8-K Exhibit 99.1, Nov 4, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000114085926000040/exhibit991-resegmentation.htm (published Nov 4, 2026)
- S23: American Oncology Network acquisition announcement (8-K Exhibit 99.1, Oct 21, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000110465926117576/tm2627778d1_ex99-1.htm (published Oct 21, 2026)
- S24: Credit agreement (8-K Item 1.01, Aug 5, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000110465926090691/tm2621845d1_8k.htm (published Aug 5, 2026)
- S25: 2026 proxy statement (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000162828026003061/cor-20260122.htm (published Jan 22, 2026)
- S26: Senior notes offering (8-K, Feb 13, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1140859/000110465926015272/tm265391d5_8k.htm (published Feb 13, 2026)
